| . | Overall (n = 539) . | Death/MI (n = 42) . | No death/MI (n = 497) . | P-value . |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 58.6 ± 9.2 | 64.2 ± 8.5 | 58.1 ± 9.1 | <0.001 |
| Male | 297 (55%) | 27 (64%) | 270 (54%) | 0.14 |
| Body mass index (kg/m2) | 27.0 ± 4.1 | 26.6 ± 3.4 | 27.0 ± 4.2 | 0.49 |
| CAD risk factors (n = 532) | ||||
| Hypertension | 251 (47%) | 25 (60%) | 226 (46%) | 0.06 |
| Hyperlipidaemia | 196 (37%) | 22 (52%) | 174 (36%) | 0.02 |
| Diabetes | 93 (17%) | 15 (36%) | 78 (16%) | 0.002 |
| Smoking | 184 (35%) | 17 (41%) | 167 (34%) | 0.24 |
| Family history of CAD | 286 (54%) | 21 (50%) | 265 (54%) | 0.36 |
| Medication (n = 534) | ||||
| Aspirin | 404 (76%) | 38 (91%) | 366 (74%) | 0.01 |
| Statin | 356 (67%) | 35 (83%) | 321 (65%) | 0.01 |
| Beta-blocker | 325 (61%) | 32 (76%) | 293 (60%) | 0.02 |
| ACE inhibitor/ARB | 190 (36%) | 23 (55%) | 167 (34%) | 0.01 |
| Calcium-channel blocker | 141 (26%) | 17 (41%) | 124 (25%) | 0.03 |
| Type of chest pain (n = 533) | 0.06 | |||
| Typical angina | 165 (31%) | 16 (39%) | 149 (30%) | – |
| Atypical angina | 188 (35%) | 17 (42%) | 171 (35%) | – |
| Non-specific chest pain | 180 (34%) | 8 (20%) | 172 (35%) | – |
| PET perfusion imaging | ||||
| Abnormal hyperaemic MBF | 259 (48%) | 32 (76%) | 227 (46%) | <0.001 |
| CCTA findings | ||||
| CACS (n = 535), median (IQR) | 52.9 (0–312) | 320.9 (87.2–1365.9) | 39.0 (0.0–281.4) | <0.001 |
| Normal coronary arteries | 118 (22%) | 0 (0%) | 118 (24%) | <0.001 |
| Non-obstructive CAD | 119 (22%) | 6 (14%) | 113 (23%) | 0.14 |
| Obstructive CAD | 302 (56%) | 36 (86%) | 266 (54%) | <0.001 |
| High-risk plaque | 127 (24%) | 20 (48%) | 107 (22%) | <0.001 |
| . | Overall (n = 539) . | Death/MI (n = 42) . | No death/MI (n = 497) . | P-value . |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 58.6 ± 9.2 | 64.2 ± 8.5 | 58.1 ± 9.1 | <0.001 |
| Male | 297 (55%) | 27 (64%) | 270 (54%) | 0.14 |
| Body mass index (kg/m2) | 27.0 ± 4.1 | 26.6 ± 3.4 | 27.0 ± 4.2 | 0.49 |
| CAD risk factors (n = 532) | ||||
| Hypertension | 251 (47%) | 25 (60%) | 226 (46%) | 0.06 |
| Hyperlipidaemia | 196 (37%) | 22 (52%) | 174 (36%) | 0.02 |
| Diabetes | 93 (17%) | 15 (36%) | 78 (16%) | 0.002 |
| Smoking | 184 (35%) | 17 (41%) | 167 (34%) | 0.24 |
| Family history of CAD | 286 (54%) | 21 (50%) | 265 (54%) | 0.36 |
| Medication (n = 534) | ||||
| Aspirin | 404 (76%) | 38 (91%) | 366 (74%) | 0.01 |
| Statin | 356 (67%) | 35 (83%) | 321 (65%) | 0.01 |
| Beta-blocker | 325 (61%) | 32 (76%) | 293 (60%) | 0.02 |
| ACE inhibitor/ARB | 190 (36%) | 23 (55%) | 167 (34%) | 0.01 |
| Calcium-channel blocker | 141 (26%) | 17 (41%) | 124 (25%) | 0.03 |
| Type of chest pain (n = 533) | 0.06 | |||
| Typical angina | 165 (31%) | 16 (39%) | 149 (30%) | – |
| Atypical angina | 188 (35%) | 17 (42%) | 171 (35%) | – |
| Non-specific chest pain | 180 (34%) | 8 (20%) | 172 (35%) | – |
| PET perfusion imaging | ||||
| Abnormal hyperaemic MBF | 259 (48%) | 32 (76%) | 227 (46%) | <0.001 |
| CCTA findings | ||||
| CACS (n = 535), median (IQR) | 52.9 (0–312) | 320.9 (87.2–1365.9) | 39.0 (0.0–281.4) | <0.001 |
| Normal coronary arteries | 118 (22%) | 0 (0%) | 118 (24%) | <0.001 |
| Non-obstructive CAD | 119 (22%) | 6 (14%) | 113 (23%) | 0.14 |
| Obstructive CAD | 302 (56%) | 36 (86%) | 266 (54%) | <0.001 |
| High-risk plaque | 127 (24%) | 20 (48%) | 107 (22%) | <0.001 |
Values are expressed as mean ± standard deviation or n (%).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CACS, coronary artery calcium score; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; IQR, interquartile range; MBF, myocardial blood flow; MI, myocardial infarction; PET, positron emission tomography.
| . | Overall (n = 539) . | Death/MI (n = 42) . | No death/MI (n = 497) . | P-value . |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 58.6 ± 9.2 | 64.2 ± 8.5 | 58.1 ± 9.1 | <0.001 |
| Male | 297 (55%) | 27 (64%) | 270 (54%) | 0.14 |
| Body mass index (kg/m2) | 27.0 ± 4.1 | 26.6 ± 3.4 | 27.0 ± 4.2 | 0.49 |
| CAD risk factors (n = 532) | ||||
| Hypertension | 251 (47%) | 25 (60%) | 226 (46%) | 0.06 |
| Hyperlipidaemia | 196 (37%) | 22 (52%) | 174 (36%) | 0.02 |
| Diabetes | 93 (17%) | 15 (36%) | 78 (16%) | 0.002 |
| Smoking | 184 (35%) | 17 (41%) | 167 (34%) | 0.24 |
| Family history of CAD | 286 (54%) | 21 (50%) | 265 (54%) | 0.36 |
| Medication (n = 534) | ||||
| Aspirin | 404 (76%) | 38 (91%) | 366 (74%) | 0.01 |
| Statin | 356 (67%) | 35 (83%) | 321 (65%) | 0.01 |
| Beta-blocker | 325 (61%) | 32 (76%) | 293 (60%) | 0.02 |
| ACE inhibitor/ARB | 190 (36%) | 23 (55%) | 167 (34%) | 0.01 |
| Calcium-channel blocker | 141 (26%) | 17 (41%) | 124 (25%) | 0.03 |
| Type of chest pain (n = 533) | 0.06 | |||
| Typical angina | 165 (31%) | 16 (39%) | 149 (30%) | – |
| Atypical angina | 188 (35%) | 17 (42%) | 171 (35%) | – |
| Non-specific chest pain | 180 (34%) | 8 (20%) | 172 (35%) | – |
| PET perfusion imaging | ||||
| Abnormal hyperaemic MBF | 259 (48%) | 32 (76%) | 227 (46%) | <0.001 |
| CCTA findings | ||||
| CACS (n = 535), median (IQR) | 52.9 (0–312) | 320.9 (87.2–1365.9) | 39.0 (0.0–281.4) | <0.001 |
| Normal coronary arteries | 118 (22%) | 0 (0%) | 118 (24%) | <0.001 |
| Non-obstructive CAD | 119 (22%) | 6 (14%) | 113 (23%) | 0.14 |
| Obstructive CAD | 302 (56%) | 36 (86%) | 266 (54%) | <0.001 |
| High-risk plaque | 127 (24%) | 20 (48%) | 107 (22%) | <0.001 |
| . | Overall (n = 539) . | Death/MI (n = 42) . | No death/MI (n = 497) . | P-value . |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 58.6 ± 9.2 | 64.2 ± 8.5 | 58.1 ± 9.1 | <0.001 |
| Male | 297 (55%) | 27 (64%) | 270 (54%) | 0.14 |
| Body mass index (kg/m2) | 27.0 ± 4.1 | 26.6 ± 3.4 | 27.0 ± 4.2 | 0.49 |
| CAD risk factors (n = 532) | ||||
| Hypertension | 251 (47%) | 25 (60%) | 226 (46%) | 0.06 |
| Hyperlipidaemia | 196 (37%) | 22 (52%) | 174 (36%) | 0.02 |
| Diabetes | 93 (17%) | 15 (36%) | 78 (16%) | 0.002 |
| Smoking | 184 (35%) | 17 (41%) | 167 (34%) | 0.24 |
| Family history of CAD | 286 (54%) | 21 (50%) | 265 (54%) | 0.36 |
| Medication (n = 534) | ||||
| Aspirin | 404 (76%) | 38 (91%) | 366 (74%) | 0.01 |
| Statin | 356 (67%) | 35 (83%) | 321 (65%) | 0.01 |
| Beta-blocker | 325 (61%) | 32 (76%) | 293 (60%) | 0.02 |
| ACE inhibitor/ARB | 190 (36%) | 23 (55%) | 167 (34%) | 0.01 |
| Calcium-channel blocker | 141 (26%) | 17 (41%) | 124 (25%) | 0.03 |
| Type of chest pain (n = 533) | 0.06 | |||
| Typical angina | 165 (31%) | 16 (39%) | 149 (30%) | – |
| Atypical angina | 188 (35%) | 17 (42%) | 171 (35%) | – |
| Non-specific chest pain | 180 (34%) | 8 (20%) | 172 (35%) | – |
| PET perfusion imaging | ||||
| Abnormal hyperaemic MBF | 259 (48%) | 32 (76%) | 227 (46%) | <0.001 |
| CCTA findings | ||||
| CACS (n = 535), median (IQR) | 52.9 (0–312) | 320.9 (87.2–1365.9) | 39.0 (0.0–281.4) | <0.001 |
| Normal coronary arteries | 118 (22%) | 0 (0%) | 118 (24%) | <0.001 |
| Non-obstructive CAD | 119 (22%) | 6 (14%) | 113 (23%) | 0.14 |
| Obstructive CAD | 302 (56%) | 36 (86%) | 266 (54%) | <0.001 |
| High-risk plaque | 127 (24%) | 20 (48%) | 107 (22%) | <0.001 |
Values are expressed as mean ± standard deviation or n (%).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CACS, coronary artery calcium score; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; IQR, interquartile range; MBF, myocardial blood flow; MI, myocardial infarction; PET, positron emission tomography.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
